...
ento-img

Entero Therapeutics, Inc., Common Stock

ENTO

NAQ

$0.62

-$0.01

(-1.59%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.11M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
33.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.37
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.18 L
$14.51 H
$0.62

About Entero Therapeutics, Inc., Common Stock

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameENTOSectorS&P500
1-Week Return8.77%-0.94%-2.6%
1-Month Return31.63%-5.08%-1.08%
3-Month Return99.36%-10.62%3.45%
6-Month Return-65.01%-6.18%8.57%
1-Year Return-83.2%1.98%24.3%
3-Year Return-99.99%-0.93%25.58%
5-Year Return-100%33.84%84.07%
10-Year Return-100%102.52%185.12%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue571.14K537.40K106.21K29.27K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.09,"profit":true},{"date":"2022-12-31","value":18.6,"profit":true},{"date":"2023-12-31","value":5.13,"profit":true}]
Gross Profit(571.14K)(537.40K)(106.21K)(29.27K)[{"date":"2020-12-31","value":-57114500,"profit":false},{"date":"2021-12-31","value":-53740000,"profit":false},{"date":"2022-12-31","value":-10620700,"profit":false},{"date":"2023-12-31","value":-2927400,"profit":false}]
Gross Margin----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses26.43M56.70M12.68M15.77M[{"date":"2020-12-31","value":46.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.36,"profit":true},{"date":"2023-12-31","value":27.81,"profit":true}]
Operating Income(26.43M)(59.06M)(12.68M)(15.77M)[{"date":"2020-12-31","value":-2643276800,"profit":false},{"date":"2021-12-31","value":-5905688800,"profit":false},{"date":"2022-12-31","value":-1267806600,"profit":false},{"date":"2023-12-31","value":-1577082700,"profit":false}]
Total Non-Operating Income/Expense(12.08M)(1.84M)(1.96M)(44.09K)[{"date":"2020-12-31","value":-1207882800,"profit":false},{"date":"2021-12-31","value":-184301100,"profit":false},{"date":"2022-12-31","value":-195904000,"profit":false},{"date":"2023-12-31","value":-4408800,"profit":false}]
Pre-Tax Income(32.67M)(58.54M)(14.63M)(15.79M)[{"date":"2020-12-31","value":-3267146600,"profit":false},{"date":"2021-12-31","value":-5853784900,"profit":false},{"date":"2022-12-31","value":-1462964200,"profit":false},{"date":"2023-12-31","value":-1579498300,"profit":false}]
Income Taxes15.11M26.52M126.56K326.37K[{"date":"2020-12-31","value":56.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.48,"profit":true},{"date":"2023-12-31","value":1.23,"profit":true}]
Income After Taxes(47.78M)(85.06M)(14.76M)(16.12M)[{"date":"2020-12-31","value":-4778438200,"profit":false},{"date":"2021-12-31","value":-8505892400,"profit":false},{"date":"2022-12-31","value":-1475620700,"profit":false},{"date":"2023-12-31","value":-1612135000,"profit":false}]
Income From Continuous Operations(32.67M)(58.54M)(14.63M)(15.79M)[{"date":"2020-12-31","value":-3267146600,"profit":false},{"date":"2021-12-31","value":-5853784900,"profit":false},{"date":"2022-12-31","value":-1462964200,"profit":false},{"date":"2023-12-31","value":-1579498300,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(32.67M)(58.54M)(14.63M)(15.79M)[{"date":"2020-12-31","value":-3267146600,"profit":false},{"date":"2021-12-31","value":-5853784900,"profit":false},{"date":"2022-12-31","value":-1462964200,"profit":false},{"date":"2023-12-31","value":-1579498300,"profit":false}]
EPS (Diluted)(61.36K)(46.51K)(3.57K)(88.81)[{"date":"2020-12-31","value":-6135944.94,"profit":false},{"date":"2021-12-31","value":-4650605.8,"profit":false},{"date":"2022-12-31","value":-357124.29,"profit":false},{"date":"2023-12-31","value":-8881.36,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ENTO
Cash Ratio 0.02
Current Ratio 5.34

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ENTO
ROA (LTM) -27.07%
ROE (LTM) -15.28%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ENTO
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ENTO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.07
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Entero Therapeutics, Inc. share price today?

Entero Therapeutics, Inc. (ENTO) share price today is $0.62

Can Indians buy Entero Therapeutics, Inc. shares?

Yes, Indians can buy shares of Entero Therapeutics, Inc. (ENTO) on Vested. To buy Entero Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENTO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Entero Therapeutics, Inc. be purchased?

Yes, you can purchase fractional shares of Entero Therapeutics, Inc. (ENTO) via the Vested app. You can start investing in Entero Therapeutics, Inc. (ENTO) with a minimum investment of $1.

How to invest in Entero Therapeutics, Inc. shares from India?

You can invest in shares of Entero Therapeutics, Inc. (ENTO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ENTO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Entero Therapeutics, Inc. shares
What is Entero Therapeutics, Inc. 52-week high and low stock price?

The 52-week high price of Entero Therapeutics, Inc. (ENTO) is $14.51. The 52-week low price of Entero Therapeutics, Inc. (ENTO) is $0.18.

What is Entero Therapeutics, Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Entero Therapeutics, Inc. (ENTO) is

What is Entero Therapeutics, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Entero Therapeutics, Inc. (ENTO) is 0.07

What is Entero Therapeutics, Inc. dividend yield?

The dividend yield of Entero Therapeutics, Inc. (ENTO) is 0.00%

What is the Market Cap of Entero Therapeutics, Inc.?

The market capitalization of Entero Therapeutics, Inc. (ENTO) is $1.11M

What is Entero Therapeutics, Inc.’s stock symbol?

The stock symbol (or ticker) of Entero Therapeutics, Inc. is ENTO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top